Introduction
Chronic kidney disease (CKD) is associated with a greatly increased risk of cardiovascular disease (CVD), which rises exponentially as kidney function declines 1 . Traditional cardiovascular risk factors, such as older age, hypertension, diabetes mellitus, obesity, dyslipidaemia and smoking, only account for part of this increased risk 2 . Moreover, therapies targeting traditional risk factors of cardiovascular risk, such as hyperlipidaemia, have yielded disappointing results in the CKD population 3, 4 . Over the past decade, emerging knowledge regarding the aetiology of CVD in CKD has shifted the focus from traditional to novel risk factors, including uremic toxins, in an effort to explain this increased CVD burden.
This recognition has led to a surge in uremic toxin research with the annual number of publications in this novel area tripling between 2000 and 2012 5 . Many potential uremic toxins have been identi ied and variously classi ied according to their physicochemical properties 6 and/or their origin 7 ( Table 1) . From this research, two uremic toxins, indoxyl sulphate (IS) and p-cresyl sulphate (PCS), have surfaced as key nephro-and cardiovascular toxins that are potentially amenable to therapeutic manipulation by a variety of strategies. This review focuses on IS and PCS with respect to their toxicokinetics, nephrovascular 7 classifi ca on systems.
Discussion
The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects in these referenced studies gave informed consent to participate in these studies.
Toxicokinetics
IS (MW 213 Daltons) and PCS (MW 188 Daltons) emanate from colonic bacterial fermentation of dietary protein 8 . Colonic microbiota produce tryptophanase, which degrades tryptophan into indole, and 4-hydroxyphenylacetate decarboxylase (4-Hpd), which degrades tyrosine and phenylalanine into p-cresol (Figure 1) 9 . Indole and p-cresol are then absorbed into the blood from the colon where they are metabolised by the liver and intestinal membrane to IS and PCS, respectively. Both are predominantly bound to albumin in the serum and share the same albumin-binding site, Sudlow II, to which they are non-covalently bonded 10 . In the healthy population, more than 99% of the toxins are protein-bound in serum. However, as their concentrations rise, such as in CKD, binding saturation occurs resulting in an increase in the unbound fraction of IS and PCS (free IS and free PCS), reaching levels of approximately 10% in haemodialysis patients 11 . Organic anion transporters (OAT) play an important role in the uptake of IS and PCS by a diverse range of tissues, including renal proximal tubules, vascular endothelial cells, vascular smooth muscle cells and osetoblasts 12 . This aligns with the sites vulnerable to clinical manifestations of uremia 13 . OAT1 and 3 are the main isoforms from the OAT family responsible for the transport of IS and PCS 14, 15 . OAT are also involved in renal elimination via active tubular secretion from the proximal tubules.
Patients with CKD exhibit an exponential rise in serum levels of IS and PCS with declining kidney function due to augment levels of toxin-producing intestinal micro-organisms 16 , impaired protein assimilation in the small intestine 17 and reduced renal clearance (Table 2) 7 .
Nephrovascular toxicity
Both IS and PCS have demonstrated extensive pro-in lammatory and oxidative stress properties in vitro and have shown to be independent predictors of all-cause mortality, CVD and kidney disease progression in the CKD population. 21 as well as promotes aortic calci ication and wall thickening 22 . In addition, oral administration of IS has resulted in increased serum creatinine with decreased clearance 23 , increased glomerular sclerosis 24 , increased glomerular hypertrophy and expression of transforming growth factor 22 . Although few animal studies have investigated the effects of PCS, a recent study reported similar effects to IS, with increased ibronectin and α-smooth muscle actin expression in the kidney, resulting in signi icant nephrosclerosis 25 .
Observational studies have consistently shown independent associations between at least one of the toxins (IS, free IS, PCS or free PCS) and all-cause mortality. In a cohort of 175 haemodialysis patients, Bammens et al. reported high free PCS serum levels (above median) was an independent predictor of all-cause mortality (HR = 2.28, 95% con idence interval [CI] = 1.12-4.64) 26 , which was similarly reported in a cohort of 139 CKD patients (CKD Stage II-IV [dialysis]) 27 . Interestingly, total PCS was not associated with mortality in these studies, which further supports the important role and the metabolic activity of the free form. IS has also demonstrated an independent association with all-cause mortality in a cohort of 521 haemodialysis patients (HR = 1.30, 95% CI = 1.01, 1.69) 28 . Furthermore, free IS was associated with all-cause mortality in 112 haemodialysis patients, following adjustment for age, diabetes status and albumin, whereas no association between mortality and IS was found 29 . An association between free PCS and cardiovascular events was demonstrated in 499 CKD patients, independent of both Framingham risk factors (HR = 1.40, 95% CI = 1.07-1.84) and kidney function (HR = 1.49, 95% CI = 1.09-2.04) 30 . Similarly, an independent association with cardiovascular events and IS was reported in a cohort of 70 CKD patients 31 . In addition, both total IS and PCS independently predicted renal progression (de ined as decrements in estimated glomerular function [Egfr] >50% or progression to end-stage renal disease) in 268 CKD patients 32 . These indings, though not conclusive, indicate the role of IS and PCS as nephrovascular toxins.
Therapeutic opportunities
With the growing body of evidence for the nephrovascular toxicity of IS and PCS, a number of therapeutic (Table 3) . These treatment options are discussed in more detail below.
Protein restriction
It has been known for decades that a decrease in dietary protein intake results in decreased production of uremic toxins 33 . In particular, a recent study has shown a 37% reduction in serum concentrations of IS following a very low protein diet (0.3 g/kg/ day) compared to a low-protein diet (0.6 g/kg/day) in the CKD population 34 . Nonetheless, the ef icacy of low-protein diets in early-to-moderate-stage CKD is controversial, and in the dialysis population, best-practice guidelines recommend moderate-to-high protein intakes (1.0-1.2 g/kg/day) 35 . Low-protein and very low protein diets have been associated with modest improvement in outcomes in the CKD population, including reducing mortality 36 . Nonetheless, concerns with the overall value of achieving such low intakes have been raised. First, malnutrition associated with low-protein diets was observed in the largest CKD study assessing protein intake to date, Modi ication of Diet in Renal Disease (MDRD) study, even under close monitoring 37 . Without close monitoring, the risk of malnutrition on low-protein diets in this population is even greater. Second, protein-restricted diets are often plagued by poor dietary compliance, with few studies achieving greater than 50% of targeted restriction 38 . These igures suggest the risks of limited monitoring and poor compliance may challenge the overall bene it of recommending a lowprotein diet in this population.
Pre-and pro-biotics
The use of prebiotics, 'indigestible' carbohydrates that stimulate gut bacteria, and probiotics, supplements of living bene icial bacteria, is becoming increasingly popular in mainstream medicine. Furthermore, in nephrology the increased intestinal generation of IS and PCS, coupled with the disturbed microbiota observed in the CKD population 16 , suggests a theoretical bene it for pre-and pro-biotic therapy. Support for the mechanism behind this therapy was demonstrated in a probiotic intervention study in a cohort of haemodialysis patients, which reported both serum IS and faecal lora as outcome measures. This approach illustrated a 30% decrease in serum IS (p < 0.01), in conjunction with a decline in faecal enterobacteria (E. coli) (p < 0.05), which has one of the highest observed enzymatic activities for IS production 39 . Furthermore, a prebiotic intervention in 12 healthy volunteers demonstrated a signi icant reduction in faecal p-cresol (65%) and indole (25%) along with increases in faecal Bifidobacteria and Lactobacillus and a decrease in Bacteroidaceae 40 . The Bacteroidaceae family includes the Bacteroides fragilis species, which has a high enzymatic activity for p-cresol production 41 . The combination of the decrease in PCS-producing bacteria (Bacteroidaceae) and the increase in PCS-and-IS-suppressing bacteria (Bifidobacteria and Lactobacillus) supports the proposed mechanistic rationale for the signi icant reduction in faecal p-cresol and indole.
Our group recently published a systematic review that included 19 intervention studies measuring the effectiveness of pre-, pro-and/or syn-biotics on IS and/or PCS levels in adults 42 . Despite the signi icant limitations of the reviewed studies, including case-series study design and limited studies in kidney disease, pre-, pro-and/or syn-biotics appeared to be bene icial for suppressing IS and PCS production. Following publication of this review, the results of a further randomised, placebo-controlled, cross-over trial in the healthy population was published, illustrating a signi icant decrease in urinary p-cresol (a marker of p-cresol generation) and an increase in faecal bifidobacteria with prebiotic therapy 43 . Despite the limited number of studies in kidney disease populations, the clear mechanistic plausibility of this therapy makes this a promising treatment opportunity warranting further investigation.
Dialysis
Dialytic removal of uremic toxins has been shown to improve both life expectancy and quality of life in patients with end-stage kidney disease 44 . Nonetheless, even in the early stages of dialysis, the limited clearance of protein-bound solutes was identi ied 45 . Indeed, it wasn't until two large-scale randomised-controlled trials, HEMO 46 and ADEMEX 47 , failed to show a survival advantage associated with increased removal of small water-soluble uremic toxins and even middle molecules above current standards that the focus turned to protein-bound uremic toxins.
The high protein-binding af inity of IS and PCS markedly limits their dialytic removal, averaging <15% of the dialytic urea clearance 48 . To date, a number of studies have evaluated the clearance of protein-bound uremic toxins using different types of dialysis. The introduction of highlux dialysis membranes showed no improvement in clearance of these two toxins 49 . This inding was not unexpected, given that the increased permeability of high-lux membranes is isolated primarily to large, non-protein-bound solutes. The addition of convective transport to conventional dialysis has also been investigated, albeit with con licting indings. Two cross-over studies reported opposing effects of haemodia iltration on dialysis clearance, although both studies failed to show a superior bene it on posttreatment plasma concentration of the toxins 50, 51 . In contrast, Meert et al. reported a 20% reduction in serum PCS following 9 weeks of haemodial itration 52 . This disparity, however, may be owing to the lower dialysate low rate used for the conventional haemodialysis (500 vs. 620 mL/ min), thereby exaggerating the effect of convective transport.
Compared to low-lux membranes, super-lux membranes have shown superior removal of IS, although this inding is at least partially explained by increased albumin removal 53 . Another method that may enhance the ef iciency of removal of proteinbound uremic retention solutes, such as IS and PCS, is addition of a sorbent to the dialysate, which may achieve increases in clearance of more than two-fold 54 . Furthermore, a pilot study using two dialyzers in series showed an enhanced clearance of IS and PCS (by 57% and 66%, respectively) by increasing the dialyzer mass transfer area coef icient and dialysate low compared to conventional practice 55 . A more recent study has shown similar bene its achieved with standard equipment, albeit requiring extended treatment 56 . These options appear to be making some headway in targeting clearance of toxins, such as IS and PCS. However, despite the signi icant advances in dialysis technology, the ef icacy, safety and cost-effectiveness of achieving sustained decreases in serum concentrations of IS and PCS by these techniques require further investigation.
Charcoal adsorbent treatment
The oral charcoal adsorbent, AST-120 (Kremezin, Kureha Chemical Industry, Tokyo, Japan), is available in Asian countries, where it is approved for treatment of CKD 57 . The sorbent's mechanism of action has been proposed to be related to its role in intestinal absorption of indole and p-cresol. In fact, metabolomic research has identi ied IS as the principal serum metabolite to differentiate the effects of AST-120, and therefore, reduction in IS serum concentration has been used to demonstrate the effectiveness of AST-120 58 . Furthermore, Schulman et al. 57 illustrated a dose-dependent reduction in serum IS (approximately 40%, 20%, 2.5%), with ranging doses of AST-120 (9 g, 6.3 g, 2.7 g, respectively) in 163 CKD patients. Of note however, AST-120 absorbs a number of other uremic toxins, including hippuric acid, and its effect on PCS absorption is less apparent 58 . Apart from the effects of AST-120 on serum IS, there have been a number of intervention studies investigating clinical outcomes in response to this treatment. A 6-month controlled trial (n = 35) showed the administration of AST-120 signi icantly lowered the concentration of serum and urinary IS, and patients who showed a greater decrease in urinary IS also showed a more marked suppression of the progression of CKD (de ined as 1/serum creatininetime plot) 59 . Another study (n = 40) reported signi icant improvements in low-mediated dilatation (3.24% vs. 4.01%, p = 0.009), a measure of endothelial dysfunction, and a 65% reduction in oxidized/reduced glutathione ratio, a marker of oxidative stress, with a 47% decrease in IS 60 .
Licensee However, a recent endpoint study suggested no bene it with AST-120 supplementation. The results of the Phase III trial (n = 2035), Evaluating Prevention of Progression In Chronic kidney disease (EPPIC), conducted in the US, demonstrated no difference between placebo and AST-120 in CKD progression (de ined as time to initiation of dialysis, transplantation or doubled of serum creatinine) 61 . The authors have suggested that compliance may have been a contributing factor to the negative outcome.
Indeed, the compliance issues reported in EPPIC may have been related in part to the well-characterised side effects of AST-120. Being an oral adsorbent, it has the potential to bind to other bene icial nutrients along with uremic toxins and requires signi icant luid intake to support its effect. Furthermore, the treatment has a high pill burden and is associated with constipation and gastrointestinal upset. These side effects could potentially contribute to the initiation of dialysis, therefore negating the theoretical bene it of this form of therapy.
OAT modulators
Animal models have suggested that the decreased renal excretion of uremic toxins in kidney disease may be related to the reduced expression of OAT. This decreased OAT expression in renal tubules has been con irmed by renal biopsies in CKD patients 62 . Statins have been shown in vitro to upregulate speci ic OAT transcription localised in the renal tubular cells, suggesting a possible therapeutic modality for enhancing IS and PCS excretion 63 . So far, however, there has been no report of serum or renal clearance bene its associated with statins, via OAT modulation. This is probably due to the overlap of substrate speciicity where the effect of single-OAT gene modulation is likely to be minimal in overall transportation 64 . Other well-known OAT inhibitors, probenecid and cilastatin, have also been shown in vitro to dosedependently decrease IS-stimulated cardiac myocyte hypotrophy 65 . More important, these OAT antagonists did not affect cardiac cell viability. Nonetheless, probenecid and cilastatin are also non-speci ic OAT inhibitors and therefore may concurrently decrease the renal excretion of IS through OAT in the proximal tubular cells. This limits the application of this mechanism, as it currently stands, for therapeutic intervention in the clinical setting.
Antioxidants and intracellular pathway inhibitors
The pathogenic actions of IS and PCS are thought to stem from the induction of reactive oxygen species (ROS), which activate the nuclear factor kappa B (NF-kB) pathway, resulting in both oxidative stress and stimulation of pro-in lammatory cytokines. An in vitro study in human renal proximal tubular cells has supported this through dose-dependent increases in oxidative stress and activation of NF-kB over a range of IS concentrations 19 . In addition, in vitro studies have found treatment with antioxidants and NF-kB inhibitors dosedependently inhibit the ibrotic and oxidative effects of IS and PCS 19, 20 . At present, these indings summarise only experimental data and, therefore, require translation and testing in vivo before consideration as a treatment for IS and PCS.
Conclusion
IS and PCS are important proteinbound uremic retention solutes that are found in increased concentrations in the serum of patients with CKD due to both enhanced colonic production, increased colonic substrate and reduced renal clearance. They have been shown to exert renal and cardiovascular toxicity in vitro and animal studies and have been associated with increased CVD, kidney disease progression and all-cause mortality in the CKD population. Overall evidence for treatments targeting the generation and clearance of IS and PCS is growing. In particular, pre-and pro-biotic therapy, although a relatively new concept in CKD, appears to be a novel and promising treatment strategy when considering a targeted, tolerable and cost-ef icient therapy. Further clinical studies are warranted to determine the effectiveness of pre-and pro-biotics in achieving clinically important decreases in IS and PCS and, ultimately, improvements in patient-level outcomes.
